Article Information
History
- June 2, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Prof. Dr. Sue Ann Costa Clemens1,2,
- Dr. Eveline Pipolo Milan3,
- Dr Eduardo Sprinz4,
- Dr José Cerbino Neto5,
- Dr. Filippo Pacciarini6,
- Dr. Ping Li6,
- Dr. Hui-Ling Chen6,
- Dr. Igor Smolenov6,
- Prof. Dr. Andrew Pollard1 and
- Dr. Ralf Clemens7,*
- 1Oxford Vaccine Group, Department of Pediatrics, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom
- 2Siena University, Siena, Italy
- 3Centro de Estudos e Pesquisa em Moléstias Infecciosas Ltda. (CEPCLIN), Natal, Brazil
- 4Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
- 5D’Or Institute for Research and Education, Rio de Janeiro, Brazil
- 6Clover Biopharmaceuticals Inc., Cambridge, MA, USA
- 7International Vaccine Institute, Seoul, Republic of Korea
- ↵*Corresponding Author
Dr. Ralf Clemens, International Vaccine Institute, SNU Research Park, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826 Korea, E-mail: clemens.ralf{at}outlook.com
Posted June 02, 2022.
Homologous and heterologous boosting of the ChAdOx1-S1-S COVID-19 vaccine with the SCB-2019 vaccine candidate: a randomized, observer-blinded, controlled, phase 2 study
